KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ClearPoint Neuro (CLPT) EBITDA (2018 - 2025)

ClearPoint Neuro's EBITDA history spans 13 years, with the latest figure at -$5.3 million for Q3 2025.

  • For Q3 2025, EBITDA fell 2.01% year-over-year to -$5.3 million; the TTM value through Sep 2025 reached -$22.8 million, down 20.99%, while the annual FY2024 figure was -$19.7 million, 12.03% up from the prior year.
  • EBITDA for Q3 2025 was -$5.3 million at ClearPoint Neuro, up from -$5.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.2 million in Q1 2021 and bottomed at -$7.1 million in Q2 2023.
  • The 5-year median for EBITDA is -$4.7 million (2023), against an average of -$4.7 million.
  • The largest annual shift saw EBITDA tumbled 199.06% in 2021 before it skyrocketed 33.75% in 2024.
  • A 5-year view of EBITDA shows it stood at -$4.0 million in 2021, then decreased by 12.23% to -$4.5 million in 2022, then decreased by 5.3% to -$4.7 million in 2023, then decreased by 20.02% to -$5.6 million in 2024, then increased by 6.59% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for CLPT's EBITDA are -$5.3 million (Q3 2025), -$5.7 million (Q2 2025), and -$6.2 million (Q1 2025).